Pharmaceutical Technology's In the Lab eNewsletter
Mass spectrometry should be utilized effectively to optimize biosimilar analysis, which can reduce development time and cost.
Indu Javeri
Advertisement
INDU JAVERI is president and CEO, CuriRx, Inc., Wilmington, MA.
Articles by Indu Javeri
Advertisement
Latest Updated Articles
Accelerating Biosimilar AnalysisOctober 2nd 2019
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why Big Pharma Is Betting Billions on Protein Degraders for Cancer
2
GSK Acquires Nuvalent for $10.6 Billion in Lung Cancer Push
3
USP Reports Drug Discontinuations on the Rise
4
Enhancing Clinical Data Infrastructure for AI Research: A Strategic Guide for Pharma Professionals
5